The treatment

AVLX-144

Avilex Pharma is a clinical stage company developing best in class neuroprotectants

Avilex Pharma is developing AVLX-144, a PSD-95 inhibitor and best-in-class neuroprotectant to treat patients suffering from acute conditions such as subarachnoid hemorrhage and acute ischemic stroke.

Avilex Pharma is also developing a pipeline of neuroprotectants for multiple Indications. Inhibition of PSD-95 has been clinically validated and AVLX-144 provides a unique  opportunity for orphan and broad indications

Learn more
Current Status

Acute ischemic stroke

4

Every 4 minutes, someone dies of stroke - third most common cause of death – leading cause of long-term disability

34b

Stroke costs the United States an estimated $34 billion each year (includes cost of healthcare, medicine & missed work days).

1

Only one drug tissue plasminogen activator (tPA) is approved for ischemic stroke, but less than 10% receive treatment.

34b

Stroke costs the United States an estimated $34 billion each year (includes cost of healthcare, medicine & missed work days).

Learn more
Latest News

from Avilex Pharma

December 17, 2021

Press Release: Avilex Pharma and Simcere announce strategic partnership

Avilex Pharma and Simcere announce strategic partnership to develop and commercialize novel treatments for acute ischemic stroke in greater china

Read More

May 26, 2021

Successfully completes phase 1 clinical trial

A compound developed by Danish researchers from the University of Copenhagen could be the key to one of the greatest unsolved challenges in modern medicine.…

Read More

December 17, 2021

Press Release: Avilex Pharma and Simcere announce strategic partnership

Avilex Pharma and Simcere announce strategic partnership to develop and commercialize novel treatments for acute ischemic stroke in greater china

Read More

All news
Get in touch